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ABSTRACT: Research links high blood pressure variability (BPV) with stroke and cerebrovascular disease, however, its 
association with cognition remains unclear. Moreover, it remains uncertain which BP-derived parameter (ie, variability or 
mean) holds more significance in understanding vascular contributions to cognitive impairment. We searched PubMed, 
Embase, PsycINFO, and Scopus and performed a meta-analysis of studies that quantified the association between resting 
BPV with dementia or cognitive impairment in adults. Two authors independently reviewed all titles, abstracts, and full-texts 
and extracted data, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-Analysis of 
Observational Studies in Epidemiology guidelines. Study quality was assessed using the (modified) Newcastle-Ottawa Scale. 
A multilevel meta-analysis was used, which included effect sizes for both BPV and mean BP, with a combined end point of 
dementia or cognitive impairment as primary outcome. In the primary analysis, 54 effect sizes were extracted from 20 studies, 
with a total analytical sample of n=7 899 697. Higher systolic BPV (odds ratio [OR], 1.25 [95% CI, 1.16–1.35]), mean systolic 
pressure (OR, 1.12 [95% CI, 1.02–1.29]), diastolic BPV (OR, 1.20 [95% CI, 1.12–1.29]), and mean diastolic pressure (OR, 
1.16 [95% CI, 1.04–1.29]) were associated with dementia and cognitive impairment. A direct comparison showed that mean 
BP effect sizes were less strong than BPV effect sizes (OR, 0.92 [95% CI, 0.87–0.97], P<0.01), indicating that the relative 
contribution of BPV exceeded that of mean BP. Methodological and statistical heterogeneity was high. Secondary analyses 
were less consistent as to whether BPV and mean BP were differentially associated with dementia subtypes and cognitive 
domains. Future studies are required to investigate BPV as a target for dementia prevention. (Hypertension. 2021;78: 
1478–1489. DOI: 10.1161/HYPERTENSIONAHA.121.17797.) • Data Supplement
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High blood pressure (BP) during mid-life is widely recognized as a modifiable risk factor for late-life dementia.1,2 Subsequently, lowering high BP with 
antihypertensive medication during mid-life is a recom-
mended strategy to prevent dementia.3,4 Yet, several 
uncertainties remain that hamper clinical guidelines for 
the management of BP to maintain brain health, includ-
ing optimal BP targets in mid- to late-life and the choice 
of antihypertensive drug(s).5 The inconsistency in find-
ings raises the possibility that BP-related factors beyond 
absolute BP level or treat-to-target BP could be impor-
tant for dementia prevention and early intervention.
A body of empirical work indicates that oscillations 
in BP between consecutive measures hold additional 
prognostic significance, alongside mean BP level, for 
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organ damage.6,7 Previous meta-analyses have reported 
associations of high BP variability (BPV) with stroke and 
cerebral small vessel disease (CSVD), underscoring the 
importance of BPV to brain health.8–10 An association 
between BPV with dementia and cognitive impairment 
was reported as part of a larger meta-analysis on BP and 
cognition but was limited to only 2 studies.11
Evaluating the current evidence regarding BPV and 
cognitive function may inform evidence-based clinical 
practice regarding BP management to preserve brain 
health. Therefore, the objective of this review is to quan-
tify the association between intraindividual BPV with 
the risk of dementia or cognitive impairment. A second 
objective is to compare the magnitude of the association 
between BPV and cognitive outcomes with the effect 
sizes for mean BP.
METHODS
The authors declare that all supporting data are available within 
the article and its Data Supplement. The protocol of this sys-
tematic review was registered with the International Prospective 
Register of Systematic Reviews (CRD42017081977) and pub-
lished.12 The study followed the Meta-Analysis of Observational 
Studies in Epidemiology and the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses guidelines.13,14
Sources and Search Strategy
A comprehensive search of PubMed (Medline), Embase, 
PsycINFO, and Scopus without language restriction was 
performed from database inception to April 20, 2021 (Data 
Supplement). Two reviewers (R.A.A. de Heus and M. Opozda) 
independently screened titles and abstracts to assess eligi-
bility. Full text was evaluated if eligibility was not clear from 
the abstract. Inconsistencies were resolved by consulting a 
third reviewer (P.J. Tully). Articles and conference abstracts of 
case-control studies, prospective cohorts, database registries, 
cross-sectional studies, and (secondary analyses of) random-
ized controlled trials were eligible for inclusion. A hand-search 
was performed of the articles selected for full-text review and 
of narrative reviews,15,16 supplementing the electronic search. 
Where necessary, we contacted authors of relevant articles to 
request additional data.
Eligibility Criteria
Studies were considered eligible if they investigated an adult 
sample (≥18 years), examined BPV using repeated mea-
surements of BP at rest, assessed a prespecified cognitive 
outcome (see below), and reported the association between 
BPV and study outcome(s), or could provide additional anal-
yses. No restriction was placed on sample size or length of 
follow-up. Reporting the association between mean BP and 
study outcome(s) was not a prespecified inclusion criterion. 
Because the field is lacking a gold standard for quantifying 
intraindividual BPV, all common metrics were eligible, pri-
oritizing the coefficient of variation where studies reported 
multiple metrics (Data Supplement).17 Studies including 
persons with baseline dementia were excluded if they did 
not report the association of BPV with cognition separately 
for those without dementia. Studies in patients with recent 
stroke, Parkinson disease, receiving hemodialysis or renal 
denervation, revascularization, or facing orthostatic chal-
lenge were ineligible.
Outcomes
The primary outcome was the odds for dementia or cogni-
tive impairment attributable to BPV or mean BP. Studies that 
reported incident dementia, cognitive impairment, a composite 
of dementia or cognitive impairment, or compared dementia 
and nondementia groups were included. This approach was 
chosen to maximize the number of studies in the primary 
analysis and because dementia and cognitive impairment 
Nonstandard Abbreviations and Acronyms
BP blood pressure
CSVD cerebral small vessel disease
GRADE  Grading of Recommendations Assess-




• High blood pressure variability may be a predictor for 
the risk of dementia or cognitive impairment.
• The relative contribution of variability in blood pressure 
exceeded that of mean blood pressure.
What Is Relevant?
• Variability might be a novel blood pressure-derived 
parameter to be taken into account in hypertension 
management.
• Blood pressure variability might be a future target to 
prevent dementia.
Summary
In this meta-analysis, that included 20 studies for the 
primary outcome, both a higher mean level of blood 
pressure as well as a higher degree of blood pres-
sure variability were associated with greater odds for 
dementia or cognitive impairment. Effect sizes for 
blood pressure variability were larger than effect sizes 
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represent a continuum of the same syndrome. The defini-
tion of dementia was criterion-referenced and was based on 
International Classification of Disease criteria, Diagnostic and 
Statistical Manual of Mental Disorders criteria, an adjudicated 
expert panel or the prescription of antidementia drugs, inclu-
sive of any dementia, Alzheimer disease, Vascular demen-
tia, or mixed cause. The definition of cognitive impairment 
was any of the following definitions that were standardized 
within studies: criterion-referenced diagnosis of mild cogni-
tive impairment,18,19 a cognitive test score below a predefined, 
clinical cutoff point, a predefined between-assessment 
decline, or a score below age and sex appropriate normative 
data, all based on standardized tests of global cognitive func-
tion or assessing specific cognitive domains. Studies using 
self-reported measures were ineligible.
The secondary outcomes were other effect sizes report-
ing on the association between BPV and cognition. This 
included (standardized) mean cognitive function scores in 
the lowest versus highest group of BPV or mean BP (eg, 
quartiles) and conversely (standardized) mean differences 
in BPV and mean BP when grouped by cognitive function. 
Furthermore, effect sizes of β/r family reporting the correla-
tion between BPV and cognition on a continuous scale were 
extracted for analyses.
Data Extraction
Data were independently extracted by 3 reviewers (R.A.A. 
de Heus, M. Opozda, and E.J.L. Lee) and verified by a fourth 
reviewer (P.J. Tully). We extracted information pertaining to 
study identification (first author, year, country, and study name), 
design characteristics (design, population, sample size, and 
follow-up), population characteristics (age, sex, education, 
use of antihypertensive medication, and comorbidities), char-
acteristics of BP(V) (measurements, timing, interval, setting, 
device, and metrics), dementia adjudication (criteria, subtypes, 
consensus panel, and number of end points), cognitive testing 
(tests used, domains assessed, and criteria for impairment or 
decline), effect sizes (most adjusted effect sizes), and list of 
adjusted covariates. When studies reported multiple metrics of 
BPV, we prioritized the methods that adjusted for mean BP 
level (eg, coefficient of variation instead of SD). The association 
of mean BP with study outcomes was extracted when available. 
Effect sizes of mean BP for dementia or cognitive impairment 
were standardized to 10/5 mm Hg increase as not all stud-
ies reported the SD of mean BP. In instances where different 
levels of adjustment were made for mean and BPV data, we 
prioritized data from the same model to ensure equivalence in 
covariate adjustment.
Quality Assessment
The risk of bias within each study was assessed independently 
by 2 reviewers (R.A.A. de Heus and M. Opozda) using modi-
fied versions of the Newcastle-Ottawa Scale, for cross-sec-
tional, case-control, and cohort designs.20 Discrepancies were 
resolved by consulting a third reviewer (P.J. Tully). Adjudication 
of the strength of evidence for the hypothesis that high 
BPV increases the risk for dementia or cognitive impairment 
was made according to the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) criteria, 
with GRADE Profiler 3.6.1.21
Deviations From Protocol
Based on preliminary data extraction and performing a paral-
lel review on BPV and CSVD, several changes were instigated 
from the published protocol.10,12 Our adjudication of the primary 
outcome was expanded, combining dementia and cognitive 
impairment together, opting to analyze the categories sepa-
rately in ancillary analysis. Second, we included cross-sectional 
studies to estimate the association between BPV with demen-
tia or cognitive impairment, opting to analyze different study 
designs separately in ancillary analysis. Also, we excluded stud-
ies assessing beat-to-beat BPV, as this metric likely represents 
a different physiological mechanism compared with 24-hour, 
day-to-day, and visit-to-visit BPV.22,23
Statistical Analysis
Data pertaining to the likelihood of dementia or cognitive 
impairment were pooled as odds ratio (OR) with 95% CIs. A 
multilevel meta-analysis was used using the metafor package 
in R version 3.5.2.24 Compared with a traditional meta-analysis, 
a multilevel meta-analysis accounts for the dependence in 
effect sizes within a study (eg, between BPV and mean BP 
from which BPV is often calculated; and dependence of sys-
tolic and diastolic BP).10 Thus a single study could contrib-
ute up to 4 effect sizes for each analysis (systolic BP and 
BPV, diastolic BP and BPV). A mixed-effects model, with a 
random intercept per study, tested fixed effect moderators for 
BP type (diastolic versus systolic) and measure (mean versus 
variability). Random-effects models (inverse-variance method) 
were used under the assumption of high sampling variability 
between studies, different BPV metrics, and cognitive function 
outcomes.25 Statistical heterogeneity was evaluated with the I2 
statistic and methodological heterogeneity was explored with 
meta-regression in Comprehensive Meta-Analysis software.26 
The presence of publication bias was evaluated with the test of 
Egger,27 Begg-Mazumdar,28 and the Duval and Tweedie trim-
and-fill funnel plot.29
Separate analyses considered key methodological and 
descriptive characteristics that might modulate the association 
between BP and dementia cognitive impairment and the differ-
ent dementia subtypes (Data Supplement). The standardized 
mean difference between groups of BPV or cognitive impair-
ment groups (dementia or impairment versus no dementia or 
impairment) were modeled with RevMan 5.3, analyzing cog-
nitive function or BPV, respectively.30 Comprehensive Meta-
Analysis software was used for the analysis of r family effect 
sizes showing the linear association between BP(V) measures 
and cognitive function.26,31
RESULTS
Study Selection and Characteristics
After duplicate removal, 2661 records were screened, 
from which 53 were retained (Figure 1). Reasons for 
exclusion after full-text review are described in Table S1 
in the Data Supplement.32–51 Twenty unique studies sam-
ples met the inclusion criteria for the primary outcome 
(analytical n=7 899 679).52–71 These comprised 8 cohort 
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one nationwide registry database (n=7 844 814), 
4 randomized controlled trials analyzed as a cohort 
(n=32 684), 3 cross-sectional studies (n=3006), and 2 
case-control studies (n=410). The timing and interval of 
exposure and outcome assessment are depicted in Fig-
ure 2. Studies’ participants had a mean age of 73±7 years 
and 58±13% women. Two study samples comprised 
a population of type II diabetes patients and 3 studies 
comprised patients with high CVD risk or hypertension. 
Eleven studies assessed visit-to-visit office BPV, 4 stud-
ies 24-hour ambulatory BPV, 4 studies day-to-day home 
BPV, and 1 study intravisit office BPV. Characteristics 
are presented in the Table and additional information in 
Tables S2 through S4.
Forty-seven records, comprising 43 unique study sam-
ples (analytical n=7 915 946) reported any of the sec-
ondary outcomes.52–59,61,63–65,68–72,76–107 Seventeen studies 
reported standardized mean difference in BPV between 
groups of cognitive function, 17 studies reported stan-
dardized mean difference in cognitive function between 
groups of BPV, and 23 studies reported the linear asso-
ciation between BPV with cognitive function. Character-
istics are presented in Tables S4 and S5.
Study Quality and GRADE Rating
Quality assessment is presented in Tables S6 through 
S8. Overall quality was deemed good in 16 studies, fair 
in one study and poor in 3 studies. In all studies, BP was 
assessed with reliable methods. Eight studies did not 
adjust their analyses of BPV for mean BP. There was 
evidence of publication bias for systolic BPV, based on 
funnel plot asymmetry and Egger test (P=0.023; Table 
S9 and Figure S1). GRADE rating of the quality of evi-
dence was very low (Table S10).
BPV and Dementia or Cognitive Impairment
Fifty-four effect sizes retrieved from 20 studies were 
included in the multilevel model (Figure 3). The model 
included 21 systolic BPV, 11 mean systolic BP, 15 dia-
stolic BPV, and 7 mean diastolic BP effect sizes. Higher 
systolic BPV was significantly associated with an 
increase in dementia/cognitive impairment (OR, 1.25 
[95% CI, 1.16–1.35]; I2=87%), as was mean systolic 
BP (OR, 1.12 [95% CI, 1.02–1.29]; I2=82%). Similar 
results were found for diastolic BPV (OR, 1.20 [95% CI, 
1.12–1.29]; I2=83%) and mean diastolic BP (OR, 1.16 
[95% CI, 1.04–1.29]; I2=3%). When effect sizes were 
directly compared in the multilevel meta-analysis, the 
association of mean BP with the primary outcome was 
less strong compared with the association of BPV with 
the primary outcome (OR, 0.92 [95% CI, 0.87–0.97]; 
P<0.01 for comparison). Diastolic effect sizes were 
also less strong than systolic effect sizes in a direct 
comparison including both BPV and mean BP (OR, 
0.96 [95% CI, 0.95–0.98]; P<0.001 for comparison). 
Overall, heterogeneity was high.
Meta-Regression and Subgroup Analyses
Results of the meta-regression on the primary outcomes 
are presented in Table S11. Higher mean BP of the 
study population was associated with an attenuation in 
association, and thus lower effect sizes, for both systolic 
Figure 1. Flow diagram of included studies.
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BPV (coefficient, −0.003 [95% CI, −0.005 to −0.001]) 
and diastolic BPV (coefficient, −0.030 [95% CI, −0.039 
to −0.021]; Figure 4). In addition, effect sizes for BPV 
were associated with lower age, female sex, low educa-
tion, shorter interval between consecutive BP measures, 
shorter total interval of BP measurements, lower body 
mass index, and diabetes.
Subgroup analyses by methodological characteristics 
are presented in Figures S2 and S3. Systolic BPV analy-
ses indicated heterogeneity for study quality, follow-up 
length, BP measurement (oscillometric versus other), BP 
measurement interval, and study region. Studies includ-
ing only patients with hypertension were heterogenous 
for systolic BPV compared with other studies. For dia-
stolic BPV, there was evidence of heterogeneity between 
study designs and type of BPV metric.
The analysis stratified by subtypes of the primary 
outcome supported the main findings, indicating an 
association between BPV and risk of dementia (any 
type), Alzheimer disease, vascular dementia, cognitive 
Figure 2. Schematic overview of included studies for the primary analysis.
X axis represents time in years and each study is presented at the mean age of the study population at baseline. Chuang et al54 (2016) and 
Matsumoto et al62 (2018) are missing from this overview because these studies (abstract only) did not report the mean age of the study 
population. A indicates ambulatory blood pressure measurements (24-h); H, home blood pressure measurements; S, single-visit (within-visit BP 
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impairment, and cognitive decline (Figure S4). However, 
the main finding of stronger effect sizes for BPV com-
pared with mean BP was not supported in these sub-
types, with the exception of Alzheimer disease (P<0.01).
Secondary Outcomes
Results of the secondary outcomes analyses were 
generally consistent with the primary outcome analysis 
(Figures S5–S7), although evidence was sparse. Com-
paring BP(V) between groups of cognitive function 
indicated higher systolic BPV in those with cognitive 
impairment, with no difference observed for mean 
BP. Conversely, we observed lower general cogni-
tive function in those with high BPV compared with 
low BPV. In addition, general cognitive function and 
BPV were associated in studies reporting β/r effect 
sizes, although for diastolic BPV this was only a trend. 
Associations between cognition and mean BP in sec-
ondary analyses were inconsistent, with mean systolic 
BP associated with improved memory and attention/
executive/psychomotor indices.
Table. Characteristics of Included Studies for the Primary Analysis
First author Year Country
Name of 









Alpérovitch52 2014 France Three-City Cohort Community-dwelling 
elderly (65+)
6506 DSM-IV criteria, expert 
panel
Visit-to-visit 6.8 y 
(MED)
Böhm53 2015 Multi-national ONTARGET/ 
TRANSCEND
RCT Patients with high 
CVD risk (55+)
24 593 MMSE <24 at follow-up Visit-to-visit 4.7 y 
(MED)
Chuang,54* 2016 Taiwan CVDFACTS Cohort Community-dwelling 
elderly
320 MMSE <24 Visit-to-visit 13 y




Outpatients with and 
without dementia
200 DSM-IV criteria, expert 
panel
Day-to-day …
Fujiwara56 2018 Japan SEARCH Nested 
cohort
Outpatients (80+) 497 MMSE recall score ≤1 
(out of 3)
24-h ABPM 1 y




2573 Digit Symbol Substitu-
tion Test
Intravisit …




Outpatients with type 
2 diabetes (65+)
231 Mini-Cog ≤2 Day-to-day …
Lattanzi59 2014 Italy NA Case-
control





Ma60 2019 The Nether-
lands
Rotterdam Cohort General population 
(55+)
5273 DSM-III-R criteria, expert 
panel
Visit-to-visit 14.6 y 
(MED)
Matsumoto61* 2014 Japan Ohasama Cohort General population 
(55+)
485 MMSE <24 at follow-up Day-to-day 7.8 y 
(MED)
Matsumoto62 2018 Japan JPAD2 RCT Patients with diabetes 
(30-85)
2450 Prescription of antide-
mentia drugs or demen-
tia admission
Visit-to-visit 9 y
McDonald63 2017 England NA Cohort Community-dwelling 
elderly (65+)
302 change in MMSE after 
5 y
24-h ABPM 5 y




Outpatients with CVD 
factor(s) (70+)
201 MMSE ≤24 Visit-to-visit 3 mo
Oishi65 2017 Japan Hisayama Cohort General population 
(60+)
1674 DSM-III criteria, expert 
panel
Day-to-day 5 y
Peters66† 2008 Multi-national HYVET-COG RCT Hypertensive elderly 
(80+)
3336 DSM-IV criteria, expert 
panel
Visit-to-visit 2.2 y (M)
Rouch67 2019 France S.AGES Cohort Community-dwelling 
elderly (65+)
3319 DSM-IV criteria Visit-to-visit 2.6 y (M)












Pre-DIVA RCT Community-dwelling 
elderly
2305 DSM-IV criteria, expert 
panel
Visit-to-visit 6.4 y (M)
Yamaguchi70 2014 Japan NA Cohort General population 
(70–72)
188 ≥1 point MMSE 
decrease after 4 y
24-h ABPM 4 y




7 844 814 ICD codes/prescription 
of antidementia drugs
Visit-to-visit 6.2 y 
(MED)
ABPM, ambulatory blood pressure monitoring; AD, Alzheimer disease; BPV, blood pressure variability; CVD, cardiovascular disease; DSM, Diagnostic and Statistical Manual of 
Mental Disorders; ICD, International Classification of Diseases; M, mean; MED, median; MMSE, Mini-Mental State Examination; NA, not applicable; NINCDS-ADRDA, National Institute 
of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association; and RCT, randomized controlled trial.
*Conference abstract only. Additional information for quality assessment was retrieved from Ogawa et al73 (2008), Chuang et al74 2013, and Matsumoto et al75 2020.
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DISCUSSION
This systematic review and meta-analysis showed that 
elevated BPV is associated with a higher risk of dementia 
and cognitive impairment. Findings were generally con-
sistent across dementia subtypes and general cognitive 
impairment, although published data were sparse for 
secondary outcomes. These findings are derived from 
observational studies of generally good quality but with 
high heterogeneity and evidence of publication bias in 
the retained articles. As such, the GRADE rating and 
strength of evidence were very low for the primary out-
come, which tempers the conclusions that can be drawn.
Our findings emerge in the context of past research 
documenting associations between cognitive function 
and impaired BP regulation, such as circadian variation 
and orthostatic hypotension,95,108 as well as previous sys-
tematic reviews relating BPV to neurological outcomes, 
including acute stroke, transient ischemic attack, CSVD, 
and dementia.8–11 Here, multilevel meta-analysis model-
ing demonstrated that dementia and cognitive impair-
ment were more consistently associated with BPV than 
with mean BP. This contrasts with our previous finding 
showing BPV contributes to CSVD risk but no more than 
mean BP.10 Besides methodological differences, this dis-
crepancy can be partly explained by the timing of BP 
Figure 3. Association of blood pressure(variability) (BP(V)) 
with dementia and cognitive impairment following multilevel 
meta-analysis.
Odds ratio (OR) for mean blood pressure is presented by 10 
(systolic) or 5 (diastolic) mm Hg. OR for BPV is presented per 
1-unit change in the BPV metric. aEffect size reported separately for 
group with and without vascular risk factors or disease. bEffect sizes 
reported separately for young and old group.
Figure 4. Bubble plots of meta-regression result for mean 
blood pressure (BP) as covariate.
The size of the bubble reflects the weight of the study. Line 
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and outcome assessment. CSVD is known to be primar-
ily induced by hypertension,109 whereas the link between 
cardiovascular risk and cognitive impairment is strongest 
in mid-life, becoming more ambiguous at late-life.110 In 
addition, it is likely that the association between BPV and 
cognitive impairment is only partly attributable to CSVD, 
involving other pathways such as Alzheimer pathology, 
hypoxia and blood-brain barrier dysfunction. Conversely, 
neurodegeneration in brain regions involved in auto-
nomic control might lead to high BPV,111 as indicated by 
heterogeneity in effect sizes for diastolic but not systolic 
BPV when study designs were compared. However, this 
is not supported by evidence demonstrating intact baro-
reflex function in early dementia, hinting towards normal 
BP regulation.112 Indeed, definitive answers on the direc-
tion of causality between BP regulation and dementia 
are currently lacking.35
Our review analyzed an extensive spectrum of cog-
nitive outcomes. There were sparse published data for 
vascular dementia, mixed dementia, cognitive decline, 
and domain-specific cognitive function. As such, the 
association between BPV and secondary outcomes 
was less clear. The putative association between BP 
with dementia appears strongest for vascular dementia 
often as a result of cerebrovascular disease.5 Yet brain 
imaging studies indicate that the majority of dementia 
cases, including Alzheimer disease, have a mix of neu-
rodegenerative and vascular-type pathology evident (eg, 
amyloid-β, lacunes of vascular origin).113 The combination 
of neurodegenerative and vascular pathologies further 
underscores how BP only partly explains the neurode-
generative processes preceding dementia and that BP 
may work in concert with other nonvascular and vascu-
lar risk factors. Previously, we raised the possibility that 
the interaction between BPV and white matter hyperin-
tensities leads to impairments in processing speed and 
executive function,102 with BPV especially impacting 
periventricular white matter pathways.10
The lack of consensus on BPV measurement and 
quantification contributes substantial heterogeneity 
between studies.17 Different BPV metrics were pooled 
separately in ancillary analyses and demonstrated gener-
ally consistent results. Likewise, there was no evidence 
of heterogeneity between intravisit, 24-hour ambulatory 
BP monitoring, home BP, and visit-to-visit variability. BP 
measurement intervals of 6 months or less conferred a 
higher risk for the primary outcome than did BP intervals 
greater than 6 months. Short- and long-term BPV are 
hypothesized to both reflect arterial reflex and compli-
ance and dosing/titration of antihypertensive medica-
tions.114 Previously meta-analytic findings indicate that 
both short- and long-term BPV are associated with car-
diovascular outcomes and mortality.7
Strengths of this study include the multilevel 
approach, the large pooled analytical sample, and exten-
sive ancillary analyses. Several limitations temper the 
results of this review including evidence of publication 
bias. The retained studies were primarily undertaken 
in older aged adults (mean age 55–84 years) which 
may explain the difference in effect sizes observed 
for BPV and mean BP. Inclusion of such wide-ranging 
age groups may introduce other biases in the analyses, 
such as selection and attrition bias.115 In addition, our 
review was marked by significant heterogeneity even 
when limiting analyses to high-quality studies, implicat-
ing methodological and population characteristics as a 
source of between study heterogeneity.
Another limitation is that several studies defined 
visit-to-visit BPV using BP measurements that were 
taken during follow-up, introducing bias due to informa-
tive censoring.109 Likewise, some studies adjusted BPV 
analyses for mean BP, which may lead to an attenuation 
of effect sizes due to over-adjustment or multicollinear-
ity. These are inherent limitations of the original studies, 
which were not designed to prospectively assess BPV 
independent of mean BP. Pooled analyses are prone 
to aggregation of study-level biases, and therefore, an 
individual participant data meta-analysis might reduce 
methodological heterogeneity and offer new insights on 
the role of BPV in dementia risk.
Perspectives
In summary, this systematic review and meta-analysis 
showed that high BPV was associated with an increased 
risk of dementia and cognitive impairment, although the 
strength of evidence was low. The relative contribution 
of BPV to the risk of dementia and cognitive impairment 
exceeded that of mean BP in primarily older adult sam-
ples. Further investigation is warranted concerning the 
mechanisms through which BPV may confer heightened 
dementia risk over mean BP, and the potential of BPV as 
a target for dementia prevention.
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